FSH, a physiological activator of ovarian functions [5], can promote the expression of progranulin in ovarian carcinoma cells [19], while progranulin can promote ovarian cancer cell proliferation [19–21], likely via activation of cyclin D1 [21] and an increase in the proportion of cells in the S-phase of mitosis [20]. The gene discussed is BRD2; the disease is ovarian carcinoma.